Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

89%

8 trials in Phase 3/4

Results Transparency

11%

1 of 9 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

7(77.8%)

Phase 2

1(11.1%)

Phase 4

1(11.1%)

9Total

Phase 3(7)

Phase 2(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT00220233Phase 3Completed

Olmesartan as an add-on to Amlodipine in Hypertension

Role: lead

NCT00220220Phase 3Completed

Amlodipine as add-on to Olmesartan in Hypertension

Role: lead

NCT00311155Phase 4Completed

Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension

Role: lead

NCT00151827Phase 3Completed

Olmesartan Medoxomil in Hypertension and Renal Impairment

Role: lead

NCT00185159Phase 3Completed

Olmesartan Medoxomil in Diabetes Mellitus

Role: lead

NCT00185172Phase 3Completed

Olmesartan in Essential Hypertension

Role: lead

NCT00185185Phase 3Completed

Olmesartan Medoxomil in Atherosclerosis

Role: lead

NCT00185146Phase 2Completed

Efficacy and Safety of Pactimibe in Patients With Atherosclerosis

Role: lead

NCT00362960Phase 3Completed

Olmesartan Medoxomil and Diabetic Nephropathy

Role: lead

All 9 trials loaded